* TRACON Pharmaceuticals Inc TCON.OQ TCON.O is expected
to show no change in quarterly revenue when it reports
results on May 11.
* Refinitiv's mean analyst estimate for TRACON
Pharmaceuticals
Inc is for a loss of 42 cents per share. For the same quarter
last year, the company reported a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 0.8%
in the last three months.
* Wall Street's median 12-month price target for TRACON
Pharmaceuticals Inc is $11, above its last closing price
of $1.73.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.36 -0.35 -0.40 Missed -13.4
Sep. 30 2021 -0.32 -0.32 -0.38 Missed -17.2
Jun. 30 2021 -0.32 -0.31 -0.58 Missed -86.2
Mar. 31 2021 -0.30 -0.30 -0.33 Missed -8.2
Dec. -0.44 -0.41 -0.31 Beat 23.6
31 2020
Sep. 30 2020 -0.64 -0.65 -0.38 Beat 41.5
Jun. 30 2020 -0.73 -0.73 -0.70 Beat 3.7
Mar. 31 2020 -1.12 -1.13 -0.78 Beat 31.1
This summary was machine generated May 10 at 02:04 GMT. All
figures in US dollars unless otherwise stated